Visalia, California 93277


Purpose:

The purpose of this study is to evaluate the safety and effectiveness in lowering intraocular pressure (IOP) utilizing an experimental lotion containing 0.1% Brimonidine that is applied to the outside of one eyelid.


Study summary:

Glaucoma is the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma the most common form of glaucoma. Vision loss is caused by damage to the optic nerve. The modern goals of glaucoma management are to avoid glaucomatous damage, nerve damage, preserve visual field and total quality of life for patients with minimal side effects. Although intraocular pressure is only one of the major risk factors for glaucoma, lowering it via various pharmaceuticals and/or surgical techniques is currently the mainstay of glaucoma treatment. Intraocular pressure can be lowered with medication, usually eye drops. There are several different classes of medications to treat glaucoma with several different medications in each class. In order to prevent blindness from glaucoma, it is critical that patients take their glaucoma eye drops accurately and faithfully for the rest of their lives. Poor compliance with medications and follow-up visits is a major reason for vision loss in glaucoma patients. In addition, coordination involved in placing an eye drop in the eye is considerably more difficult and unpleasant to patients than many other therapies. Thus, localized transdermal eyelid lotion would create a leap in safety of drug delivery while at the same time rendering ocular drugs easy and non traumatic to use.


Criteria:

Inclusion Criteria: - Patients with a clinical diagnosis of stable Chronic Open Angle Glaucoma and stable Vital signs who are controlled on a stable dose of a single IOP lowering agent and who have demonstrated stable target intraocular pressure for a minimum of 3 months. - Male or Female patients aged at least 18 years of age. - Females of childbearing potential must use a reliable form of contraception throughout the study period such as celibacy, birth control pills, or condoms. - A negative urine pregnancy test result at Screening and Baseline (Day 1) for women of childbearing potential - Best-Corrected Visual Acuity of 20/800 or better in both eyes - Written informed consent. - Ability to follow instructions and likely to complete all study visits based upon patient factors such as cognition, reliability, motivation, and ability to obtain reliable transportation to study site. Exclusion Criteria: - Uncontrolled glaucoma - Glaucoma requiring more than a single agent for IOP control - Patients with a corneal thickness greater then 620 micrometers - Female patients who are pregnant, nursing, or planning a pregnancy during the study - Patient who has any situation or condition, which in the investigator's opinion, may put the patient at a significant risk, may confound the study result or may interfere significantly with the participation in the study - Uncontrolled or labile hypertension - At the conclusion of the washout period any study participant with an IOP lower than 22 or greater than 35 mmHg.


NCT ID:

NCT01345448


Primary Contact:

Principal Investigator
Padma Nanduri, MD

Michael Boone, MD
Phone: (559)627-9393
Email: drboone@visaliaeyecare.com


Backup Contact:

Email: drnanduri@envisioneye.com
Padma Nanduri, MD
Phone: 858-450-1010 ext. 134


Location Contact:

Visalia, California 93277
United States

Michael Boone, MD
Phone: 559-627-9393
Email: drboone@visaliaeyecare.com

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.